1
J Milton Harris, Antoni Kozlowski: Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications. Shearwater Polymers, Bell Seltzer Park & Gibson P A, September 30, 1997: US05672662 (405 worldwide citation)

Active esters of PEG acids and related polymers are provided that have a single propionic or butanoic acid moiety and no other ester linkages. These polymer acids have a half life in water of from about 10 to 25 minutes. For example, alpha-methoxy, omega-propionic acid succinimidyl ester of PEG ("me ...


2
Richard B Greenwald, Anthony J Martinez: Water-soluble non-antigenic polymer linkable to biologically active material. Enzon, Roberts & Mercanti, September 5, 2000: US06113906 (204 worldwide citation)

Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment site ...


3
Lisa B Shih, Frederick J Primus, Milton D Goldenberg: Diagnostic and therapeutic antibody conjugates. The Center for Molecular Medicine and Immunology, Foley & Lardner, October 15, 1991: US05057313 (150 worldwide citation)

The present invention relates to conjugates of diagnostic or therapeutic principles, such as drugs, toxins, chelators, boron compounds and detectable labels, to an antibody, in which the diagnostic or therapeutic principle is first loaded onto a polymer carrier such as an aminodextran or a polypepti ...


4
Nandini Katre, Michael J Knauf: Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation. Cetus Corporation, Janet E Hasak, Philip L McGarrigle, Albert P Halluin, April 17, 1990: US04917888 (134 worldwide citation)

A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not r ...


5
David M Goldenberg: Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments. Immunomedics, Foley & Lardner, February 10, 1998: US05716595 (130 worldwide citation)

Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use agents labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions wit ...


6
Philip E Thorpe, Rolf A Brekken: Antibody conjugate compositions for selectively inhibiting VEGF. Board of Regents The University of Texas System, Williams Morgan and Amerson, January 29, 2002: US06342221 (129 worldwide citation)

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based c ...


7
Richard S Blumberg, Neil E Simister, Wayne L Lencer: Receptor specific transepithelial transport of immunogens. The Brigham and Women s Hospital, Brandeis University, Wolf Greenfield & Sacks P C, July 11, 2000: US06086875 (126 worldwide citation)

Methods and products for modulating an immune response are provided. Pharmaceutical preparations contain a conjugate of an antigen and a FcRn binding partner. The conjugates are administered to mammals in effective amounts to modulate the immune system by stimulating the immune response against the ...


8
Richard S Blumberg, Neil E Simister, Wayne I Lencer: Receptor specific transepithelial transport of therapeutics. The Brigham and Women s Hospital, Brandeis University, Wolf Greenfield & Sacks P C, February 29, 2000: US06030613 (126 worldwide citation)

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepith ...


9
Pyare Khanna, Edwin F Ullman: Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers. Syva Company, Bertram I Rowland, March 9, 1982: US04318846 (116 worldwide citation)

Diether symmetrically substituted fluoresceins are provided having at least one anionic group and a linking functionality. Depending upon the site of substitution, the compounds can be used as fluorescers absorbing at wavelengths in excess of 500 nm or as quenchers, absorbing at wavelengths in exces ...


10
Phillip M Friden: Transferrin receptor specific antibody-neuropharmaceutical agent conjugates. Alkermes, Hamilton Brook Smith & Reynolds, June 18, 1996: US05527527 (113 worldwide citation)

The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugat ...